US12083112 — Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
Method of Use · Assigned to Eisai R&D Management Co Ltd · Expires 2036-03-03 · 10y remaining
What this patent protects
This patent protects a combination therapy for treating cancer that combines a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor.
USPTO Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R 1 is C 1-6 alkyl or C 3-8 cycloalkyl, R 2 is a hydrogen atom or C 1-6 alkoxy, and R 3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3996 |
— | lenvatinib-mesylate |
U-3996 |
— | lenvatinib-mesylate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.